Un groupe coopérateur engagé dans la recherche sur le lymphome

Ne ratez pas les présentations du LYSA au 56ème congrès de l’ASH

 

L’ASH 2014 approche et voici les travaux récents du LYSA qui seront présentés à San Francisco, qu’il s’agisse d’études LYSA ou en collaboration:  6 présentations orales et 15 posters !

Merci à tous les investigateurs LYSA pour le travail quotidien dans les études sans quoi rien de tout cela ne serait possible, merci à toutes les  équipes du LYSARC pour leur aide,

Bravo à ceux qui ont conduit ces différentes études et analyses.  N’oubliez pas de venir les soutenir, à l’oral ou devant leurs posters !!!

 

Présentations orales :

Steven Le Gouill : 146 Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study.

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Indolent Lymphoma and Mantle Cell Lymphoma

Sunday, December 7, 2014: 4:45 PM, North Building, Hall D (Moscone Center)

 

Christiane Pott : 147 MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network.

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Indolent Lymphoma and Mantle Cell Lymphoma

Sunday, December 7, 2014: 5:00 PM, North Building, Hall D (Moscone Center)

 

Remy Gressin : 148 Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group.

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Indolent Lymphoma and Mantle Cell Lymphoma

Sunday, December 7, 2014: 5:15 PM, North Building, Hall D (Moscone Center)

 

Thierry Lamy : 393 R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL):  Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group.

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Adjusting Induction Therapy in Large Cell Lymphoma

Monday, December 8, 2014: 11:00 AM, South Building, Esplanade 304-306-308 (Moscone Center)

 

Stephane Lepretre : 371 Pediatric ALL-like Therapy in Adults with T-Cell Lymphoblastic Lymphoma: Results of the Graall-Lysa LL03 Study.

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies II

Monday, December 8, 2014: 11:30 AM, West Building, 2001-2003-2014-2016 (Moscone Center)

 

Jehan Dupuis : 504 Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL)

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Hodgkin Lymphoma/ T-cell Lymphoma

Monday, December 8, 2014: 4:00 PM, South Building, Esplanade 304-306-308 (Moscone Center)

 

Présentations en Posters:

Saturday, December 6, 2014: 5:30 PM-7:30 PM, West Building, Level 1 (Moscone Center)

Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

Marie-Hélène Delfau-Larue : 1625 Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

Morgane Cheminant : 1657 Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study

Isabelle Fleury : 1659 No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I

Violaine Safar : 1721 A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients

 

Sunday, December 7, 2014: 6:00 PM-8:00 PM, West Building, Level 1 (Moscone Center)

Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II

Eva Hoster : 2977 Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network

Thierry Fest : 2998 Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster II

Frédéric Peyrade : 3042 Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)

Julien Lazarovici : 3054 Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association

Herve Ghesquieres : 3060 Updated Results Confirm Favorable Outcome of Immunocompetent Patients with Primary CNS Lymphoma Treated By C5R Protocol in Combination with Intravenous Rituximab and Intrathecal Liposomal Cytarabine: A Multicentric Prospective Phase 2 Study of the Lymphoma Study Association (LYSA)

Julien Dubreuil  : 3070 Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell

Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II

Gandhi Damaj : 3102 Concomitant Systemic and Neuro-Meningeal Non-Hodgkin’s Lymphoma: The Role of Consolidation with Intensive Chemotherapy and Autologous Stem Cell Transplantation. a Retrospective Study of 65 Cases

 

Monday, December 8, 2014: 6:00 PM-8:00 PM, West Building, Level 1 (Moscone Center)

Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

Steven Le Gouill : 4426 T3 : A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Temsirolimus (Torisel™)-CHOP-Rituximab (T-R-CHOP), Temsirolimus (Torisel™)-FC-Rituximab (T-R-FC) and Temsirolimus (Torisel™)- DHA-Rituximab (T-R-DHA) for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL), a Lysa Study

Lionel Karlin : 4430 Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III

Franck Morschhauser : 4458 A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma

Liat Vidal : 4462 Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

 

Print Friendly

LYSA’s Missions

Learn more
lymphome

What is Lymphoma?

Learn more

LYSA Research

Learn more

Take Part in a Clinical Trial

Learn more

The LYSA's Centers

Learn more

Support Research

Learn more